This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritzel, R. A. Articles by Butler, P. C. Search for Related Content PubMed PubMed Citation Articles by Ritzel, R. A. Articles by Butler, P. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE

Glucose Stimulates Pulsatile Insulin Secretion from Human Pancreatic Islets by Increasing Secretory Burst Mass: Dose-Response Relationships

Division of Endocrinology and Diabetes (R.A.R., P.C.B.), Keck School of Medicine, University of Southern California, Los Angeles, California 90033; and Endocrine Division (J.D.V.), Mayo Medical and Graduate Schools of Medicine, Mayo Clinic, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Peter C. Butler, M.D., Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, 1333 San Pablo Street, BMT-B11. E-mail: pbutler{at}usc.edu.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Insulin is secreted almost exclusively in discrete bursts, and physiological regulation is accomplished by modulation of the pulse mass. How the integrity of contiguous anatomic structures in the human pancreas (islets, splanchnic innervation, exocrine tissue, local hormones) directs the coordinated insulin secretion is not known. We posed the hypothesis that glucose stimulates insulin secretion from isolated human islets by an amplification of insulin pulse mass with no change in pulse frequency and that the glucose dose-response curve for the regulation of insulin pulse mass mirrors that recognized in vivo. Islets from five nondiabetic cadaveric donors were perifused in a recently validated perifusion system at 4 mM and subsequently at 8, 12, 16, or 24 mM glucose. The effluent was collected in 1-min intervals and used for the measurement of insulin (ELISA). Pulsatile insulin secretion was analyzed by deconvolution analysis. Total insulin secretion increased progressively (P < 0.0001). This augmentation was due to amplified pulse mass (3-fold, 24 mM vs. 4 mM glucose; P < 0.0001) with no change in pulse interval (4 min). Pulsatile insulin secretion was stimulated most effectively in a physiologic concentration range of 4–8 mM. The islet insulin content was significantly correlated to the magnitude of first and second phase insulin secretion (P < 0.0001). The quantifiable orderliness of pulsatile insulin secretion rose with escalating glucose concentration (P = 0.02). In conclusion, glucose stimulates pulsatile insulin secretion from isolated human islets by amplification of insulin pulse mass without altering pulse interval. The in vitro concentration-response relationship is comparable with that observed in vivo. These data imply that transplanted human islets should be able to reproduce glucose-regulated insulin secretion as observed in the intact human pancreas.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
INSULIN IS SECRETED in a glucose-regulated manner (1, 2). Insulin release is pulsatile with an interpulse interval of approximately 6 min (3, 4). In vivo insulin secretion in response to glucose ingestion and glucose infusion is driven by amplification of insulin pulse mass with no or little change in event frequency (5). It is of interest that pulsatile insulin secretion is demonstrable in isolated perifused islets thus pointing to an intrinsic pacemaker system (6, 7, 8, 9, 10). This pacemaker has been ascribed to oscillations in second-messenger signals and glycolysis (11). In vivo, interislet coordination of pulsatile insulin may be mediated by an intrapancreatic neural network (12, 13).

With increasing interest in the potential to use human islets in therapeutic transplantation (14), understanding the mechanism subserving glucose-regulated insulin secretion becomes important. The present study employs a recently validated method (9) for quantifying pulsatile insulin secretion from perifused islets studied at physiological glucose concentrations. We use this to test the hypothesis that increased glucose selectively amplifies insulin pulse mass in perifused human islets via an agonist dose-response curve function mirroring that inferred for the intact human pancreas in vivo. This notion has relevance to the conjecture that islet transplantation may reproduce some of the key mechanisms of normal physiological control.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Design

Islets were studied in an islet perifusion system, which has previously been described in detail and validated for quantification of pulsatile insulin release from human islets (9). The islets were exposed to a basal glucose concentration of 4 mM (n = 51 runs) for 40 min (0–40 min) followed by a step increase to 8 (n = 11 runs), 12 (n = 16 runs), 16 (n = 14 runs), or 24 mM (n = 11 runs) for 60 min (40–100 min). An equilibration period of 40 min without sample collection was allowed before the experiments (-40 to 0 min). Islets were recovered from the perifusion chamber and islet insulin content measured. The mean islet insulin content was not significantly different in islets studied at any of the stimulatory glucose concentrations 8, 12, 16, 24 mM (1344 ± 102; 1838 ± 236; 1398 ± 250; 2132 ± 151; P = not significant). Insulin concentrations in the effluent and insulin secretion from the islets are reported in mass units per islet to account for different islet sizes. Islet sizes were also measured at the beginning and the end of each perifusion experiment. For glucose dose-response relationships pulse mass is reported as a percentage-fraction of islet insulin content to isolate the effect of glucose from the impact of insulin stores on pulsatile insulin secretion.

Islet culture

Islets from the pancreas of five heart-beating organ donors (four male and one female; age, 47 ± 6 yr; body mass index, 31.5 ± 7.8 kg/m²) were isolated in the Northwest Tissue Center Seattle (R. Paul Robertson) and University of Minnesota Diabetes Institute for Immunology and Transplantation (Bernhard J. Hering). The islets were maintained in Roswell Park Memorial Institute culture medium with 5 mM glucose and 10% FBS at 37 C in humidified air containing 5% CO_2. Experiments were performed in random order starting after a minimum recovery period of 4 d following the islet isolation process.

Islet perifusion

Human islets were preincubated for 2 h at 4 mM glucose, then suspended in Bio-Gel P-2 beads (Bio-Rad Laboratories, Inc., Hercules, CA) and placed in perifusion chambers in aliquots of five to six islets. The perifusion system (ACUSYST-S, Cellex Biosciences, Inc., Minneapolis, MN) consisted of a multi-run peristaltic pump that delivered perifusate through six parallel tubing sets via a heat exchanger and six perfusion chambers at a constant rate of 0.3 ml/min. The perifusion buffers (Krebs Ringer bicarbonate buffer: NaCl 115 mM; KCl 4.7 mM; CaCl₂ 2.5 mM; MgCl₂ 1.2 mM; NaHCO₃ 5 mM, pH 7.4) were supplemented with 0.2% human serum albumin, preheated to 37 C, and oxygenized with 95% O₂ and 5% CO₂. The perifusate was delivered to the perifusion chambers containing the human islets, and the effluent was collected in 1-min intervals for determination of insulin concentrations.

Laboratory determinations

Glucose concentrations in the perifusion buffer were measured using the glucose oxidase method with a Glucose Analyzer 2 (Beckman Instruments, Brea, CA). Insulin was measured in duplicate with a two-site immunospecific ELISA as previously described (15). There is no cross-reactivity with proinsulin and split 32,33 and des-31,32 proinsulins. The less frequently occurring proinsulin intermediates split 65,66 and des-64,65 proinsulin react with a frequency of 30% and 63%, respectively. The lower detection limit is 4 pmol/liter, and the assay range is 5–2000 pmol/liter. The intraassay coefficient of variation ranged from 1.5–3.0%. The interassay coefficient of variation ranged from 3.5–4.5%.

Calculations and statistical analysis

The insulin concentration time series were analyzed by deconvolution analysis and approximate entropy (ApEn).

Deconvolution analysis is a multiparameter technique (16) to detect and quantify insulin secretory bursts, as described previously (17) and expressly validated for this perifusion system (9). Briefly, deconvolution analysis calculates underlying insulin secretion by way of two families of measures; the position, duration, mass, and amplitude of insulin secretory bursts; and a time-invariant nonpulsatile insulin secretion rate. Computations are based on the known half-life of exit of insulin from the perifusion system (0.63 min; Ref. 9).

ApEn is a model-independent and scale-invariant statistic designed to quantify the regularity or orderliness of (hormone) time series (18). Technically, ApEn measures the logarithmic likelihood that runs of patterns that are close (within r) for m contiguous observations remain close (within the tolerance width r) on subsequent incremental comparisons. This regularity metric is validated for parameter choices of r = 0.2 x SD in the individual time series and m = 1, as used here (19, 20, 21, 22). Larger ApEn indicates a higher degree of process randomness. A precise mathematical definition is given by Pincus (18).

Statistical analysis. Time evolution of measures was examined by ANOVA. ANOVA and the two-tailed Student’s unpaired t test were used to test for glucose effects on parameters of insulin pulsatility. A P value of less than 0.05 denoted significant contrasts. The EC₅₀ of glucose for insulin pulse mass and total insulin secretion was calculated by nonlinear regression analysis. The best-fit curve to the glucose concentration-response relationship for the relative proportion of the pulsatile component of insulin secretion was derived by nonlinear regression analysis. The curves of best-fit values for all other relationships were derived by linear regression analysis.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Overall pattern of insulin secretion

Islets exposed to basal glucose (4 mM) secreted insulin at a relatively steady state (Fig. 1). Following the step increase in perfusate glucose concentration there was a rapid early phase of insulin secretion, which lasted approximately 10 min, and a more prolonged second phase of secretion, which lasted until the end of the experiment (Fig. 1). Insulin secretion increased in response to increased glucose concentrations between 4 and 15 mM, reaching a maximal rate at glucose concentrations between 15 and 20 mM (Fig. 2). Both first and second phase insulin secretion were augmented with increasing stimulatory glucose concentrations (Fig. 3).

View larger version (28K): [in this window] [in a new window]   Figure 1. Insulin concentration profiles (top panels) and insulin secretion rates (derived by deconvolution analysis, bottom panels) for two representative human-islet perifusion experiments (6 islets each). Islets were maintained at 4 mM glucose during the interval 0–40 min and 12 and 24 mM glucose from 40–100 min.

View larger version (17K): [in this window] [in a new window]   Figure 2. Glucose concentration-response relationships depicted separately for insulin pulse interval (top panel), secretory burst mass (middle panel), and total insulin secretion (bottom panel) by isolated human islets in perifusion (n = 103 runs). The solid lines indicate the curve of best-fit values derived by nonlinear regression analysis.

View larger version (29K): [in this window] [in a new window]   Figure 3. Glucose concentration-response relationships for first and second-phase insulin secretion (left panels). Relationship between the mass of insulin pulses during first and second-phase secretion and absolute magnitude of first and second-phase insulin secretion (right panels) by perifused human islets (n = 52 runs). First phase insulin secretion was calculated from insulin concentration data 0–10 min after raising glucose and second phase insulin secretion from the data 10–55 min after raising glucose concentration in the perifusion buffer. The solid lines indicate the curve of best-fit values derived by linear regression analysis. The dashed lines indicate the 95% confidence intervals of the regression line.

As previously reported (8, 9, 10), insulin release from perifused human islets showed a pulsatile pattern indicated by oscillations in insulin concentration in the perifusate. Pulse height rose at higher glucose concentrations (Fig. 1). Deconvolution analysis of insulin concentration profiles confirmed that insulin is secreted from human islets in a pulsatile pattern with a mean pulse interval of 3.9 ± 0.1 min. Stepwise increases in glucose concentration induced a volley of discrete high-amplitude insulin pulses (Fig. 1, bottom panels), which we defined as early phase of insulin secretion (Fig. 1, top panels). Volleys were followed by lower amplitude insulin pulses that give rise to second phase insulin secretion.

The mass of insulin secretory bursts increased in a concentration-dependent manner with increasing glucose exposure, reaching a plateau at approximately 15 mM (Fig. 2). The EC₅₀ of perifusate glucose concentration for insulin pulse mass and total insulin secretion was in a physiologic range of glucose concentrations (5–8 mM). In contrast, the pulse interval was unchanged with increasing glucose perifusate concentration. When the proportion of insulin secretion derived from pulsatile release vs. nonpulsatile release was compared, the relative proportion attributable to pulsatile insulin secretion increased from 26.2 ± 1.5% at 4 mM to 37.6 ± 2.2% at 24 mM glucose (Fig. 4), whereas the relative proportion of nonpulsatile insulin secretion decreased (P < 0.01).

View larger version (15K): [in this window] [in a new window]   Figure 4. Glucose concentration-response relationship for the relative proportion of the pulsatile component of total insulin secretion by perifused human islets (n = 103 runs). The solid line indicates the curve of best-fit values derived by nonlinear regression analysis.

Moreover, the insulin content of the perifused islets correlated with the pulse mass of insulin secretion (Fig. 5) and first and second-phase insulin secretory-response over the glucose range studied (Fig. 6).

View larger version (23K): [in this window] [in a new window]   Figure 5. Relationship between the islet insulin content and the mean pulse mass of insulin secretion by perifused human islets (n = 52 runs). The solid line indicates the curve of best-fit values derived by linear regression analysis. The dashed lines indicate the 95% confidence intervals of the regression line.

View larger version (33K): [in this window] [in a new window]   Figure 6. Relationship between the islet insulin content and the magnitude of first (top panel) and second-phase (bottom panel) insulin secretion by perifused human islets (n = 52 runs). First phase insulin secretion was calculated from insulin concentration data 0–10 min after raising glucose and second phase insulin secretion from the data 10–55 min after raising glucose concentration in the perifusion buffer. The solid lines indicate the curve of best-fit values derived by linear regression analysis. The dashed lines indicate the 95% confidence intervals of the regression line.

The regularity of patterns of perifusate insulin concentrations was assessed with ApEn. The process randomness of insulin release decreased (lower ApEn) in a glucose concentration-dependent fashion (Fig. 7).

View larger version (14K): [in this window] [in a new window]   Figure 7. Glucose enhances the quantifiable orderliness of insulin concentration time-series (n = 103 runs) in perifused human islets. Lower ApEn denotes greater secretory regularity or reduced relative randomness of the release process. The solid line indicates the curve of best-fit values derived by linear regression analysis. The dashed lines indicate the 95% confidence intervals of the regression line.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

In the present study, we document that increasing perifusate glucose concentration results in an approximately 2- to 3-fold augmentation of insulin pulse mass (Fig. 2). These data are consistent with prior studies in rodent and human islets showing an increment in pulse mass with increased glucose, although a concentration-response relationship has not previously been established (6, 7, 8, 9, 10, 24, 25). The data are also consistent with previous studies in vivo, which have reported increased insulin pulse mass in response to glucose ingestion and glucose infusion (5, 26). These and other studies (27, 28) employed similar methods as used in the present study to analyze insulin secretion in nondiabetic humans and showed a 3- to 5-fold stimulation. This difference might arise from the fact that human islets that were kept in culture for several days have lost their intraislet capillary network and insulin release from the islet by diffusion into the buffer rather than by direct release into the bloodstream might be slowed or limited particularly from the cells in the core of the islet. Also, in the case of oral glucose ingestion in vivo, the incretin effect, which is absent in isolated islets, has been found to contribute to the insulin secretory response with 30–60% (29).

One question arising from the present and other studies showing pulsatile insulin secretion from groups of perifused islets is: how is the pulsatile insulin secretion between these islets coordinated? Whereas individual islets can secrete insulin in a pulsatile manner (10), the mechanisms that coordinate pulsatile insulin secretion from groups of islets are not yet clear, including in perifused islets (as in the present experiments). Insulin secretion arises largely (80%) from discrete insulin bursts in vivo (4, 30, 31) and in vitro in single rodent islets (25). The present estimate that approximately 35% of insulin secretion by groups of perifused islets is pulsatile presumably denotes partial coordination of in vitro insulin secretion. As discussed previously (9), the mechanisms that lead to partial coordination of pulsatile insulin secretion by perifused isolated islets may include local paracrine effects and/or electrical coupling between adjacent islets. However, it is unlikely that these are the same factors that lead to such a high (100%) degree of coordination of islets scattered in the exocrine pancreas in vivo. In vivo, available data suggest that coordination of pulsatile insulin secretion involves intra-organ neural networks. For example, following transplantation of rat islets into the liver via the portal vein, we observed a delay of approximately 30–50 d before coordinate pulsatile insulin secretion was reestablished. This interval coincided with reinnervation of the transplanted islets (32).

Estimates of the physiological frequency of pulsatile insulin secretion have evolved historically. Initial predictions yielded interpulse intervals of approximately 15 min based on RIA, sampling intervals of 1–2 min and Fourier analysis to detect stable oscillations (33, 34). Subsequent studies employing more sensitive insulin assays, neuroendocrine methods of pulse detection, direct sampling from the portal vein in dogs and humans (3, 30, 31) and in the systemic circulation in humans and pigs without or with type 2 diabetes or alloxan-induced insulinopenia report interpulse times of 4–6 min (4, 26, 35, 36). This study as well as other recent human islet perifusion studies (9, 10) describe a similar pulse frequency (5 min). The present data corroborate the stability of insulin pulse-renewal time across a wide range of glucose availability.

We report here that pulse mass is highly correlated with islet insulin content, an observation recognized recently (37). In accordance with the reduction of insulin stores in patients with type 2 diabetes (38, 39), there is a concomitant decline in posthepatically estimated insulin pulse mass in this disorder (26). Overnight inhibition by somatostatin of insulin secretion (but not synthesis) in type 2 diabetes restores pulsatile and first-phase insulin secretion (26). Accordingly, islet insulin stores are primary determinants of normal insulin secretion both in vivo and in vitro (present data).

The orderliness of pulsatile insulin secretion as determined by ApEn increases in a glucose concentration-dependent manner. This suggests that, besides an augmentation of insulin release, synchronization of oscillatory insulin release by islets (5–6 per chamber) may be enhanced by glucose. On theoretical grounds, greater (interislet) feedback signal number and/or strength would account for enhanced orderliness of the insulin secretory process (40, 41). If, as previously proposed (11), oscillations in glycolysis are the pulse generator for pulsatile insulin release by islets, an increased glycolytic flux under conditions of elevated glucose concentrations might selectively enhance the pulsatile component of insulin secretion, as observed in the present experiments.

In summary, glucose stimulates insulin secretion from isolated human islets by amplifying the mass of peptide released per burst without changing pulse frequency. The EC₅₀ of this in vitro effect is comparable to that inferred in vivo. Both first- and second-phase insulin secretion are regulated by this amplitude-specific mechanism. For any given glucose stimulus, the islet insulin content predicts the magnitude of the secretory response. Moreover, glucose acts as an interislet coordinating trigger, which enhances the ensemble orderliness of the insulin release process.

In conclusion, perifused human islets, which are independent of vascularization and innervation, reproduce key features of glucose-regulated insulin secretion observed in the intact pancreas.

	Acknowledgments

 
We acknowledge the technical expertise of Lucretia Howard (insulin assays).

	Footnotes

 
This work was supported by NIH Grant DK-61539 and the Juvenile Diabetes Research Foundation. R.A.R. is a recipient of a postdoctoral fellowship from the Deutsche Forschungsgemeinschaft (Ri 1055).

Abbreviation: ApEn, Approximate entropy.

Received August 12, 2002.

Accepted October 29, 2002.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Perley MJ, Kipnis DM 1967 Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954–1962
2. Porte Jr D 1991 Banting lecture 1990. ß-cells in type II diabetes mellitus. Diabetes 40:166–180[Abstract]
3. Pørksen N, Munn S, Steers J, Vore S, Veldhuis J, Butler P 1995 Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. Am J Physiol 269:E478–E488
4. Pørksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O 1997 In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. Am J Physiol 273:E908–E914
5. Pørksen N, Munn S, Steers J, Veldhuis JD, Butler PC 1996 Effects of glucose ingestion versus infusion on pulsatile insulin secretion. The incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes 45:1317–1323[Abstract]
6. Bergstrom RW, Fujimoto WY, Teller DC, de Haen C 1989 Oscillatory insulin secretion in perifused isolated rat islets. Am J Physiol 257:E479–E485
7. Chou HF, Ipp E 1990 Pulsatile insulin secretion in isolated rat islets. Diabetes 39:112–117[Abstract]
8. Marchetti P, Scharp DW, McLear M, Gingerich R, Finke E, Olack B, Swanson C, Giannarelli R, Navalesi R, Lacy PE 1994 Pulsatile insulin secretion from isolated human pancreatic islets. Diabetes 43:827–830[Abstract]
9. Song SH, Kjems L, Ritzel R, McIntyre SM, Johnson ML, Veldhuis JD, Butler PC 2002 Pulsatile insulin secretion by human pancreatic islets. J Clin Endocrinol Metab 87:213–221[Abstract/Free Full Text]
10. Lin JM, Fabregat ME, Gomis R, Bergsten P 2002 Pulsatile insulin release from islets isolated from three subjects with type 2 diabetes. Diabetes 51:988–993[Abstract/Free Full Text]
11. Tornheim K 1997 Are metabolic oscillations responsible for normal oscillatory insulin secretion? Diabetes 46:1375–1380[Abstract]
12. Stagner JI, Samols E 1985 Perturbation of insulin oscillations by nerve blockade in the in vitro canine pancreas. Am J Physiol 248:E516–E521
13. Sonnenberg GE, Hoffmann RG, Johnson CP, Kissebah AH 1992 Low- and high-frequency insulin secretion pulses in normal subjects and pancreas transplant recipients: role of extrinsic innervation. J Clin Invest 90:545–553
14. Robertson RP 2001 Pancreatic islet cell transplantation: likely impact on current therapeutics for type 1 diabetes mellitus. Drugs 61:2017–2020[CrossRef][Medline]
15. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME 1993 Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578–582[Abstract/Free Full Text]
16. Veldhuis JD, Carlson ML, Johnson ML 1987 The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 84:7686–7690[Abstract/Free Full Text]
17. Pørksen N, Munn S, Steers J, Veldhuis JD, Butler PC 1995 Impact of sampling technique on appraisal of pulsatile insulin secretion by deconvolution and cluster analysis. Am J Physiol 269:E1106–E1114
18. Pincus SM 1991 Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 88:2297–2301[Abstract/Free Full Text]
19. Schmitz O, Pørksen N, Nyholm B, Skjaerbaek C, Butler PC, Veldhuis JD, Pincus SM 1997 Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 272:E218–E226
20. Schmitz O, Pørksen N, Juhl C, Veldhuis JD, Butler PC, Pincus SM 1998 Disorderly insulin release processing in NIDDM assessed by approximate entropy. Diabetologia 41(Suppl 1):S84 (Abstract)
21. Pincus SM, Hartman ML, Roelfsema F, Thorner MO, Veldhuis JD 1999 Hormone pulsatility discrimination via coarse and short time sampling. Am J Physiol 277:E948–E957
22. Veldhuis JD, Pincus SM 1998 Orderliness of hormone release patterns: a complementary measure to conventional pulsatile and circadian analyses. Eur J Endocrinol 138:358–362[CrossRef][Medline]
23. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte Jr D1984 Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318–1328
24. Cunningham BA, Deeney JT, Bliss CR, Corkey BE, Tornheim K 1996 Glucose-induced oscillatory insulin secretion in perifused rat pancreatic islets and clonal ß-cells (HIT). Am J Physiol 271:E702–E710
25. Westerlund J, Bergsten P 2001 Glucose metabolism and pulsatile insulin release from isolated islets. Diabetes 50:1785–1790[Abstract/Free Full Text]
26. Laedtke T, Kjems L, Pørksen N, Schmitz O, Veldhuis J, Kao PC, Butler PC 2000 Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol 279:E520–E528
27. Tillil H, Shapiro ET, Miller MA, Karrison T, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS 1988 Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol 254:E349–E357
28. Boden G, Ruiz J, Kim CJ, Chen X 1996 Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 270:E251–E258
29. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W 1986 Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498[Abstract/Free Full Text]
30. Song SH, McIntyre SS, Shah H, Veldhuis JD, Hayes PC, Butler PC 2000 Direct measurement of pulsatile insulin secretion from the portal vein in human subjects. J Clin Endocrinol Metab 85:4491–4499[Abstract/Free Full Text]
31. Pørksen N, Grofte T, Greisen J, Mengel A, Juhl C, Veldhuis JD, Schmitz O, Rossle M, Vilstrup H 2002 Human insulin release processes measured by intraportal sampling. Am J Physiol 282:E695–E702
32. Pørksen N, Munn S, Ferguson D, O’Brien T, Veldhuis J, Butler P 1994 Coordinate pulsatile insulin secretion by chronic intraportally transplanted islets in the isolated perfused rat liver. J Clin Invest 94:219–227
33. Lang DA, Matthews DR, Peto J, Turner RC 1979 Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. N Engl J Med 301:1023–1027[Abstract]
34. O’Rahilly S, Turner RC, Matthews DR 1988 Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225–1230[Abstract]
35. Kjems LL, Kirby BM, Welsh EM, Veldhuis JD, Straume M, McIntyre SS, Yang D, Lefebvre P, Butler PC 2001 Decrease in ß-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001–2012[Abstract/Free Full Text]
36. Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA 2001 Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 50:776–784[Abstract/Free Full Text]
37. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC 2002 Induction of ß-cell rest by a ß-cell selective K_ATP-channel opener preserves ß-cell insulin stores and insulin secretion in human islets cultured at high (11mM) glucose. Diabetes 51:A13 (Abstract)
38. Wrenshall GA, Bogoch A, Ritchie RC 1952 Extractable insulin of pancreas. Correlation with pathological and clinical findings in diabetic and non-diabetic cases. Diabetes 87–107
39. Tasaka Y, Marumo K, Inoue Y, Hirata Y 1986 C-peptide immunoreactivity and insulin content in the diabetic human pancreas and the relation to the stability of diabetic serum glucose level. Acta Endocrinol (Copenh) 113:355–362
40. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD 1996 Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci USA 93:14100–14105[Abstract/Free Full Text]
41. Veldhuis JD, Straume M, Iranmanesh A, Mulligan T, Jaffe C, Barkan A, Johnson ML, Pincus S 2001 Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. Am J Physiol 280:R721–R729

This article has been cited by other articles:

				A. V. Matveyenko, J. D. Veldhuis, and P. C. Butler Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E569 - E574. [Abstract] [Full Text] [PDF]

				D. J. Michael, W. Xiong, X. Geng, P. Drain, and R. H. Chow Human Insulin Vesicle Dynamics During Pulsatile Secretion Diabetes, May 1, 2007; 56(5): 1277 - 1288. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. J. Meier, C.-Y. Lin, J. D. Veldhuis, and P. C. Butler Human Islet Amyloid Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in Isolated Human Islets Diabetes, January 1, 2007; 56(1): 65 - 71. [Abstract] [Full Text] [PDF]

				I. Quesada, M. G. Todorova, P. Alonso-Magdalena, M. Beltra, E. M. Carneiro, F. Martin, A. Nadal, and B. Soria Glucose Induces Opposite Intracellular Ca2+ Concentration Oscillatory Patterns in Identified {alpha}- and {beta}-Cells Within Intact Human Islets of Langerhans Diabetes, September 1, 2006; 55(9): 2463 - 2469. [Abstract] [Full Text] [PDF]

				J. J. Meier, I. Hong-McAtee, R. Galasso, J. D. Veldhuis, A. Moran, B. J. Hering, and P. C. Butler Intrahepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver. Diabetes, August 1, 2006; 55(8): 2324 - 2332. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. D. Veldhuis, and P. C. Butler The mass, but not the frequency, of insulin secretory bursts in isolated human islets is entrained by oscillatory glucose exposure Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E750 - E756. [Abstract] [Full Text] [PDF]

				C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]

				Y. C. Kudva, A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza, and W. L. Isley Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care, January 1, 2005; 28(1): 10 - 14. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. B. Hansen, J. D. Veldhuis, and P. C. Butler Induction of {beta}-Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves {beta}-Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 795 - 805. [Abstract] [Full Text] [PDF]

				S. H. Song, C. J. Rhodes, J. D. Veldhuis, and P. C. Butler Diazoxide Attenuates Glucose-Induced Defects in First-Phase Insulin Release and Pulsatile Insulin Secretion in Human Islets Endocrinology, August 1, 2003; 144(8): 3399 - 3405. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritzel, R. A. Articles by Butler, P. C. Search for Related Content PubMed PubMed Citation Articles by Ritzel, R. A. Articles by Butler, P. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE